All nine subjects of Phase 1 injected without any serious adverse events. Average improvement of 14.9 letters in visual acuity reported in the first six patients over a four-six month follow-up. Signs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback